Avascular Necrosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The avascular necrosis market reached a value of USD 510.6 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 866.1 Million by 2036, exhibiting a growth rate (CAGR) of 4.77% during 2026-2036.

The avascular necrosis market has been comprehensively analyzed in IMARC's new report titled "Avascular Necrosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Avascular necrosis, also called osteonecrosis, refers to a painful condition that results from a lack of blood supply to the bone. This causes the bone tissue to die, affecting a person's ability to move. Avascular necrosis most commonly affects the hip but can damage any joint bone tissue, such as ankles, jaw, knees, upper arm (humerus), and shoulders. The most prominent symptom of this ailment includes intermittent pain that arises when pressure is applied to the affected bone or while lying down. Individuals suffering from the disease may also experience stiff joints, limited range of motion, limping (if the hips or knees are affected), difficulty climbing stairs, walking, or standing, etc. The diagnosis of avascular necrosis usually depends on the patient's medical history, clinical features, and physical examination. The healthcare provider may perform specific diagnostic procedures, such as X-rays, bone scans, magnetic resonance imaging (MRI), computerized tomography (CT) scan, etc., to detect the cause of underlying indications.

The increasing cases of bone injuries, including broken bones and dislocated hips that can damage nearby blood vessels and interrupt the blood supply, are primarily driving the avascular necrosis market. Apart from this, the rising prevalence of several associated risk factors, such as joint or bone trauma, prolonged use of steroids, excessive alcohol consumption, smoking, etc., is also augmenting the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen sodium, to ease pain and improve patient well-being is creating a positive outlook for the market. Besides this, the escalating utilization of the core decompression technique, which involves surgical drilling into the region of dead bone around the joint to reduce pressure, enhance blood flow, and prevent further joint destruction, is also bolstering the market growth. Moreover, numerous pharmaceutical companies are investing in research initiatives for the development of highly potent, easier-to-administer, and economically viable painkillers. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of bone marrow aspirate concentration therapy, in which stem cells from the bone marrow are inserted into the affected part to grow new bone and improve function scores, is expected to drive the avascular necrosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the avascular necrosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for avascular necrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the avascular necrosis market in any manner.

Key Highlights:

• Every year, around 10,000 to 20,000 persons in the United States suffer from avascular necrosis of the femoral head.
• Avascular necrosis is responsible for more than 10% of all hip replacement procedures in the United States.
• It typically affects adults between 30 and 50 years of age.
• Males are more often affected than females, with an overall male-to-female ratio of 8:1.
• Avascular necrosis is more common when there is a dislocation of the ankle or subtalar joint.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the avascular necrosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the avascular necrosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current avascular necrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Avascular Necrosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the Avascular Necrosis across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the Avascular Necrosis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of Avascular Necrosis across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Avascular Necrosis by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Avascular Necrosis by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Avascular Necrosis by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with Avascular Necrosis across the seven major markets?
• What is the size of the Avascular Necrosis’ patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of Avascular Necrosis?
• What will be the growth rate of patients across the seven major markets?

Avascular Necrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Avascular Necrosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Avascular Necrosis market?
• What are the key regulatory events related to the Avascular Necrosis market?
• What is the structure of clinical trial landscape by status related to the Avascular Necrosis market?
• What is the structure of clinical trial landscape by phase related to the Avascular Necrosis market?
• What is the structure of clinical trial landscape by route of administration related to the Avascular Necrosis market?